BY
Orthobiologics maker Bioventus today released terms for its $150 million initial public offering, looking to float 8.8 million shares at between $16 and $18 per share, with plans to list on the NASDAQ Global Market under the ticker “BIOV”.
At the midpoint of its proposed range, the company would command a fully diluted market value of $566 million, and proceeds from the round should generate between $141 and $159 million, according to an SEC filing from the company.
The company originally announced plans for the IPO earlier this month, planning to use proceeds from the round to pay off its debt.
